Cardihab is one of four successful digital health companies awarded a share of $3.7M from the Australian Government’s Medical Research Future Fund (MRFF). The funds are being invested into high-growth potential digital health companies, supporting them to develop and release new products and expand into global markets, through digital health commercialisation program, ANDHealth+.
Funded by the MRFF, the ANDHealth+ program is delivered by ANDHealth, Australia’s leading digital health commercialisation organisation, providing Australia’s most promising digital health start-ups access to up to $3.7M in non-dilutive investment, alongside substantial industry mentoring and support, across a two-stage investment process.
Cardihab, successfully completed a rigorous process of qualification, including assessments by leading Australian and international investors and digital health executives, and has been selected to move into the next stage of the process.
ANDHealth CEO and Managing Director Bronwyn Le Grice said, “These companies are perfect examples of how Australian businesses are using technology to solve real health problems faced by millions of people locally and around the world. This investment will support these companies to secure the clinical evidence and customers they need to create better health and patient outcomes on a global scale."
“Due to the limited funding pools for digital health companies in Australia, ANDHealth+ is a highly competitive program that selects world-class, evidence-based technologies, as assessed by an expert industry panel and international investment committee.”
Ms LeGrice says the exhaustive process is designed to identify the companies and technology with the greatest chance of commercial growth and beneficial effect.
Cardihab CEO Helen Souris says, “to be successful in a program like this is an incredible testament to the quality of our solution, the work of our dedicated team, and the potential of our technology to have a positive impact on patients here in Australia, as well as globally.”
"Cardihab is thrilled to continue to receive funding and advice as part of the ANDHealth+ program. We will leverage this support to prepare our digital therapeutic for international markets and gather additional clinical evidence to further demonstrate our impact on patients needing cardiac rehabilitation."
We look forward to continuing our productive collaboration with ANDHealth and partners during the next phase of the program.
For more information about our programs and opportunities please contact us.